VSTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Verastem Inc (VSTM) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has positive analyst ratings and hedge fund interest, the lack of significant financial growth, declining margins, and no strong proprietary trading signals suggest waiting for a clearer entry point.
The MACD is slightly positive and contracting, indicating mild bullish momentum. RSI is neutral at 58.233, and moving averages are converging, showing no clear trend. Key resistance levels are at 6.647 and 7.017, while support levels are at 5.452 and 5.082. Pre-market price is slightly up by 0.48%, but no strong technical signals indicate a decisive trend.
Analysts maintain strong Buy ratings with price targets ranging from $15 to $19, citing promising drug pipelines and commercial launch momentum.
Hedge funds have significantly increased their buying activity by 1120.13% over the last quarter.
Financial performance in Q4 2025 shows no revenue growth, a 49.01% drop in net income, and a 70.45% decline in EPS.
Gross margin decreased by 16.49%, reflecting operational challenges.
No recent news or congress trading data to act as a catalyst.
In Q4 2025, revenue remained flat at $17.535 million YoY. Net income dropped significantly to -$32.916 million (-49.01% YoY), and EPS fell to -0.39 (-70.45% YoY). Gross margin declined to 83.51%, down 16.49% YoY, indicating reduced profitability.
Analysts are bullish on VSTM, with multiple Buy ratings and price targets between $15 and $19. They highlight the company's oncology pipeline and commercial launch momentum as key drivers. However, one analyst recently lowered their price target from $19 to $15, reflecting some caution.
